Savara (NASDAQ:SVRA) has been given a $10.00 price objective by equities researchers at Roth Capital in a research report issued to clients and investors on Tuesday, TipRanks reports. The firm currently has a “hold” rating on the stock. Roth Capital’s price target would indicate a potential downside of 11.58% from the stock’s current price.

Several other research analysts also recently commented on SVRA. Zacks Investment Research raised shares of Savara from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Thursday, April 11th. ValuEngine raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. LADENBURG THALM/SH SH reaffirmed a “buy” rating on shares of Savara in a research note on Friday, May 10th. Finally, BidaskClub raised shares of Savara from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 4th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $20.83.

Shares of NASDAQ SVRA opened at $11.31 on Tuesday. The company has a current ratio of 12.05, a quick ratio of 15.63 and a debt-to-equity ratio of 0.24. Savara has a 52 week low of $6.21 and a 52 week high of $14.06. The firm has a market capitalization of $405.24 million, a P/E ratio of -8.77 and a beta of 1.07.

Savara (NASDAQ:SVRA) last issued its earnings results on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.05. On average, analysts anticipate that Savara will post -1.55 earnings per share for the current fiscal year.

In other Savara news, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $9.03, for a total transaction of $225,750.00. Following the transaction, the insider now directly owns 184,754 shares of the company’s stock, valued at approximately $1,668,328.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO David L. Lowrance sold 7,500 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $9.02, for a total transaction of $67,650.00. Following the transaction, the chief financial officer now directly owns 2,446 shares in the company, valued at $22,062.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,261 shares of company stock worth $466,674. Insiders own 6.50% of the company’s stock.

A number of institutional investors have recently modified their holdings of SVRA. Bank of New York Mellon Corp increased its position in Savara by 8.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 80,110 shares of the company’s stock valued at $894,000 after purchasing an additional 6,124 shares during the period. BlackRock Inc. increased its position in Savara by 8.2% during the 3rd quarter. BlackRock Inc. now owns 2,170,294 shares of the company’s stock valued at $24,220,000 after purchasing an additional 164,056 shares during the period. MetLife Investment Advisors LLC increased its position in Savara by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 20,243 shares of the company’s stock valued at $226,000 after purchasing an additional 7,196 shares during the period. Teachers Advisors LLC increased its position in Savara by 15.0% during the 3rd quarter. Teachers Advisors LLC now owns 55,053 shares of the company’s stock valued at $614,000 after purchasing an additional 7,198 shares during the period. Finally, Morgan Stanley increased its position in Savara by 224.1% during the 3rd quarter. Morgan Stanley now owns 205,560 shares of the company’s stock valued at $2,294,000 after purchasing an additional 142,140 shares during the period. 47.99% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Read More: How is the discount rate different from the Federal Funds rate?

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.